CeriBell (NASDAQ:CBLL) Receives Consensus Rating of “Buy” from Brokerages

Shares of CeriBell (NASDAQ:CBLL) have been given an average rating of “Buy” by the six analysts that are presently covering the firm, Marketbeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 1 year price target among brokerages that have covered the stock in the last year is $32.60.

A number of brokerages have recently commented on CBLL. TD Cowen lifted their price target on shares of CeriBell from $31.00 to $36.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. JPMorgan Chase & Co. started coverage on CeriBell in a report on Tuesday, November 5th. They issued an “overweight” rating and a $32.00 price objective for the company. William Blair started coverage on CeriBell in a research note on Tuesday, November 5th. They set an “outperform” rating for the company. Canaccord Genuity Group started coverage on shares of CeriBell in a report on Tuesday, November 5th. They issued a “buy” rating and a $30.00 price objective on the stock. Finally, Canaccord Genuity Group increased their price target on shares of CeriBell from $31.00 to $33.00 and gave the stock a “buy” rating in a research report on Monday, December 9th.

CeriBell Price Performance

Shares of CeriBell stock opened at $23.07 on Friday. The business has a 50-day moving average price of $25.84. CeriBell has a 52-week low of $18.69 and a 52-week high of $32.75.

CeriBell (NASDAQ:CBLL) last issued its earnings results on Tuesday, November 12th. The company reported ($1.85) EPS for the quarter, missing the consensus estimate of ($0.82) by ($1.03). The business had revenue of $17.20 million during the quarter, compared to analyst estimates of $17.06 million. As a group, research analysts predict that CeriBell will post -2.46 EPS for the current year.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.